Edgewise Therapeutics (EWTX)
(Delayed Data from NSDQ)
$14.31 USD
+0.05 (0.35%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $14.34 +0.03 (0.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Edgewise Therapeutics, Inc.'s return on equity, or ROE, is -30.95% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that EWTX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
EWTX 14.31 +0.05(0.35%)
Will EWTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EWTX
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
EWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
Other News for EWTX
Janus Henderson Global Life Sciences Fund Q2 2025 Commentary
Peloton upgraded, Booking downgraded: Wall Street's top analyst calls
Raymond James Initiates Coverage on Edgewise Therapeutics (EWTX) with Strong Buy
Edgewise Therapeutics initiated with bullish view at Raymond James, here's why
PERCEPTIVE ADVISORS LLC Increases Stake in Praxis Precision Medicines Inc